82 related articles for article (PubMed ID: 16926443)
1. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
Janovick JA; Spicer TP; Bannister TD; Scampavia L; Conn PM
PLoS One; 2017; 12(8):e0181830. PubMed ID: 28767678
[TBL] [Abstract][Full Text] [Related]
3. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Ando F; Mori S; Yui N; Morimoto T; Nomura N; Sohara E; Rai T; Sasaki S; Kondo Y; Kagechika H; Uchida S
Nat Commun; 2018 Apr; 9(1):1411. PubMed ID: 29650969
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants.
Kuramoto R; Kise R; Kanno M; Kawakami K; Ikuta T; Makita N; Inoue A
PLoS One; 2024; 19(5):e0303507. PubMed ID: 38748623
[TBL] [Abstract][Full Text] [Related]
5. V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology.
Erdélyi LS; Hunyady L; Balla A
Front Endocrinol (Lausanne); 2023; 14():1173601. PubMed ID: 37293495
[TBL] [Abstract][Full Text] [Related]
6. A cAMP-biosensor-based assay for measuring plasma arginine-vasopressin levels.
Doi K; Kawakami K; Ikuta T; Inoue A
Sci Rep; 2024 Apr; 14(1):9453. PubMed ID: 38658606
[TBL] [Abstract][Full Text] [Related]
7. Target immobilization on glass microfiber membranes as a label-free strategy for hit identification.
Wang Y; He Y; Ye X; Zhang Y; Huang X; Liu H; Dong W; Yang D; Guo D
Anal Bioanal Chem; 2023 Nov; 415(27):6743-6755. PubMed ID: 37730920
[TBL] [Abstract][Full Text] [Related]
8. Functional Rescue of Inactivating Mutations of the Human Neurokinin 3 Receptor Using Pharmacological Chaperones.
Anderson RC; Hanyroup S; Song YB; Mohamed-Moosa Z; van den Bout I; Schwulst AC; Kaiser UB; Millar RP; Newton CL
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562976
[TBL] [Abstract][Full Text] [Related]
9. Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones.
Szalai L; Sziráki A; Erdélyi LS; Kovács KB; Tóth M; Tóth AD; Turu G; Bonnet D; Mouillac B; Hunyady L; Balla A
Front Pharmacol; 2022; 13():811836. PubMed ID: 35153784
[TBL] [Abstract][Full Text] [Related]
10. Misfolded G Protein-Coupled Receptors and Endocrine Disease. Molecular Mechanisms and Therapeutic Prospects.
Ulloa-Aguirre A; Zariñán T; Jardón-Valadez E
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830210
[TBL] [Abstract][Full Text] [Related]
11. Assistance for Folding of Disease-Causing Plasma Membrane Proteins.
Juarez-Navarro K; Ayala-Garcia VM; Ruiz-Baca E; Meneses-Morales I; Rios-Banuelos JL; Lopez-Rodriguez A
Biomolecules; 2020 May; 10(5):. PubMed ID: 32392767
[TBL] [Abstract][Full Text] [Related]
12. New insights into the transcriptional regulation of aquaporin-2 and the treatment of X-linked hereditary nephrogenic diabetes insipidus.
Jung HJ; Kwon TH
Kidney Res Clin Pract; 2019 Jun; 38(2):145-158. PubMed ID: 31189221
[TBL] [Abstract][Full Text] [Related]
13. Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.
Marinko JT; Huang H; Penn WD; Capra JA; Schlebach JP; Sanders CR
Chem Rev; 2019 May; 119(9):5537-5606. PubMed ID: 30608666
[TBL] [Abstract][Full Text] [Related]
14. Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.
Milano S; Carmosino M; Gerbino A; Svelto M; Procino G
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29125546
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
16. The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases.
Vukićević T; Schulz M; Faust D; Klussmann E
Front Pharmacol; 2016; 7():23. PubMed ID: 26903868
[TBL] [Abstract][Full Text] [Related]
17. X-Linked Recessive form of Nephrogenic Diabetes Insipidus in a 7-Year-Old Boy.
Janchevska A; Tasic V; Gucev Z; Krstevska-Konstantinova M; Cheong HI
Balkan J Med Genet; 2014 Dec; 17(2):81-5. PubMed ID: 25937802
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic effect of statins on nephrogenic diabetes insipidus.
Bonfrate L; Procino G; Wang DQ; Svelto M; Portincasa P
J Cell Mol Med; 2015 Feb; 19(2):265-82. PubMed ID: 25594563
[TBL] [Abstract][Full Text] [Related]
19. Using pharmacological chaperones to restore proteostasis.
Wang YJ; Di XJ; Mu TW
Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
[TBL] [Abstract][Full Text] [Related]
20. Chaperoning G protein-coupled receptors: from cell biology to therapeutics.
Tao YX; Conn PM
Endocr Rev; 2014 Aug; 35(4):602-47. PubMed ID: 24661201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
